Hyperfine, Inc. (HYPR)

Hyperfine, Inc. (HYPR) — VMCI valuation read

Composite valuation read on HYPR: VMCI 39/100 against a Healthcare sector median of 50. The 11-point below-median print is the headline number for Hyperfine, Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for HYPR: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on HYPR: HYPR trades at 15.0x earnings, 17% below the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of 3.2x is the binding constraint on the bear case. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

HYPR rose 2.0% over the trailing 7 days, with a -12.4% read on a 30-day basis.